January 2025

43rd Annual J.P. Morgan Healthcare Conference

Innovating to Transform the Lives of Patients and Their Families

Jazz Pharmaceuticals

Markella

EPIDIOLEX® patient diagnosed with Dravet syndrome

Transforming Lives. Redefining Possibilities.

Caution Concerning Forward-Looking Statements

This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company's growth prospects and future financial and operating results, including the ability of the Company's portfolio to drive long-term shareholder value; expectations with respect to indication expansion opportunities; 2024 total, neuroscience and oncology revenue guidance and the Company's expectations related thereto; the Company's ability to drive significant cash flow generation; the Company's commercial expectations, including with respect to revenue diversification and its expectations for significant growth; the Company's expectations with respect to the commercial potential of its products and product candidates, including the blockbuster potential for Epidiolex, the peak potential of zanidatamab, growth opportunities for Rylaze, Epidiolex/Epidyolex, Xywav and Ziihera and Zepzelca's potential approval as a first line therapy, and the potential regulatory paths related thereto; the value and growth potential of its products; the Company's net product sales and goals for net product sales from new and acquired products; the Company's views and expectations relating to its patent portfolio, including with respect to expected patent protection; planned or anticipated clinical trial events, including with respect to initiations, enrollment and data read-outs, and the anticipated timing thereof, and planned or anticipated regulatory submissions and filings and other regulatory matters, including potential approvals, including the timing thereof; and other statements that are not historical facts. These forward-looking statements are based on the Company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of and revenue from Xywav, Rylaze, Zepzelca, Epidiolex / Epidyolex, Ziihera and other key marketed products; effectively launching and commercializing the Company's other products and product candidates; the successful completion of development and regulatory activities with respect to the Company's product candidates; obtaining and maintaining adequate coverage and reimbursement for the Company's products; the time-consuming and uncertain regulatory approval process, including the risk that the Company's current and/or planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all; the costly and time-consuming pharmaceutical product development and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients such as those experienced, and expected to be experienced, by the Company; regulatory initiatives and changes in tax laws; market volatility; protecting and enhancing the Company's intellectual property rights and the Company's commercial success being dependent upon its obtaining, maintaining and defending intellectual property protection for its products and product candidates; delays or problems in the supply or manufacture of the Company's products and product candidates; complying with applicable U.S. and non-U.S. regulatory requirements, including those governing the research, development, manufacturing and distribution of controlled substances; government investigations, legal proceedings and other actions; identifying and consummating corporate development transactions, financing these transactions and successfully integrating acquired product candidates, products and businesses; the Company's ability to realize the anticipated benefits of its collaborations and license agreements with third parties; the sufficiency of the Company's cash flows and capital resources; the Company's ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; the Company's ability to meet its projected long-term goals and objectives, in the time periods that the Company anticipates, or at all, and the inherent uncertainty and significant judgments and assumptions underlying the Company's long-term goals and objectives; the completion of financial closing procedures, final audit adjustments and other developments that may arise that would cause the Company's expectations with respect to the Company's 2024 revenue guidance to differ, perhaps materially, from the financial results that will be reflected in the Company's audited consolidated financial statements for the fiscal year ended December 31, 2024; and other risks and uncertainties affecting the Company, including those described from time to time under the caption "Risk Factors" and elsewhere in the Company's Securities and Exchange Commission filings and reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2023 as supplemented by the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and its future filings and reports. Other risks and uncertainties of which the Company is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this presentation are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by the Company on its website or otherwise. The Company undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Jazz Pharmaceuticals

Jennie
Xywav patient living with IH

Our Purpose

is to innovate to transform the lives of patients and their families.

Who We Are

We are focused on developing life-changing medicines for people with serious diseases, often with limited or no therapeutic options, so they can live their lives more fully.

Caroline
Rylaze patient diagnosed with ALL / LBL

ALL/LBL = acute lymphoblastic leukemia / lymphoblastic lymphoma; IH = idiopathic hypersomnia.

Positioned to Drive Long-term Shareholder Value

PIPELINE

*Zanidatamab and Zepzelca **indication expansion opportunities**; additional pipeline programs under development*

COMMERCIAL

Growth** and **diversified revenues** expected to generate **significant cash flow

CORPORATE DEVELOPMENT

Financial strength** to transact and well-positioned to be **partner of choice

Growing and Diversified Commercial Portfolio

2018 Revenue $1.9 billion

74%
of revenues driven by Xyrem in 2018

Launched / Acquired Products

xywav™
Epidiolex®
Epidyolex® cannabidiol Oral solution
RYLAZE asparaginase erwinia chrysanthemi (recombinant)-rywn for injection 10mg/0.5mL per vial
ZEPZELCA (lurbinectedin) for injection 4 mg

2021 Revenue $3.1 billion

41%
of revenues driven by Xyrem in 2021



2024 Guidance[1] $4.0 - $4.1 billion

11%
of revenues[2] driven by Xyrem and AG royalties in 3Q24



- Oncology + Epidiolex + Other Revenues
- Xyrem Revenue + AG Royalty Revenue
- Xywav Revenue

AG royalties = high-sodium oxybate authorized generic royalty revenues. [1]The company expects that for the year ended December 31, 2024, reported total, neuroscience and oncology revenues will meet the guidance range provided on November 6, 2024. Jazz Pharmaceuticals plc has not finalized its financial results for the year ended December 31, 2024, and actual results may differ; [2]Chart based on revenue as reported in 3Q24.

Strategic Transactions Driving Growth and Expanding Capabilities

ZEPZELCA
Rapidly Accretive Transaction

- Rapidly established as **treatment of choice** in 2L SCLC
- **>$1.1B**[1] in revenue since launch in mid-2020
- **Positive Phase 3 results** from IMforte trial; Plan to submit **sNDA for 1L ES-SCLC in 1H25**

GW ACQUISITION
Transformational Transaction

- **Durable** and **long-lived asset** in Epidiolex
- **>$2.7 billion**[2] in revenue since acquisition mid-2021
- Epidiolex **poised** to reach **blockbuster status in 2025**
- Expanded operational footprint and **in-house R&D capabilities**

ZANIDATAMAB
Broad Oncology Development Transaction

- Significant **regulatory progress** with **extensive development program ongoing**
- Path to approval in **1L GEA** with anticipated **sBLA submission in 2025**
- **$2B+ peak sales potential**

2019 → **2021** → **2022**

WELL-POSITIONED FOR CORPORATE DEVELOPMENT

FINANCIAL STRENGTH

- **$2.6B** in cash, cash equivalents and investments[3]
- **~$1.0B** cash from operations[4]
- **$885M** undrawn revolving credit facility[5]

PARTNER OF CHOICE

- Demonstrated global commercial **footprint and capabilities**
- A **leader in neuroscience**
- **Rapidly growing** oncology business
- In-house **development expertise**
- **Track record of maximizing** asset potential

1L/2L = first- and second-line; ES = extensive stage; GEA = gastroesophageal adenocarcinoma; R&D = research and development; sBLA = supplemental biologics license application; SCLC = small cell lung cancer; sNDA = supplemental new drug application.
[1]Net product sales from launch in July 2020 to September 30, 2024; [2]Net product sales from May 2021 to September 30, 2024; [3]As of September 30, 2024; [4]For the nine months ended September 30, 2024; [5]As of December 31, 2024.

Track Record of Successfully Growing and Diversifying Commercial Portfolio

Expect to meet 2024 total, neuroscience and oncology revenue guidance[1]

20 Consecutive Years

YoY Revenue Growth

2005 – 2024G

13.5% Total Revenue CAGR

2018 – 2024G midpoint[2]



2024G = 2024 financial guidance as provided by Jazz Pharmaceuticals plc on November 6, 2024; CAGR = compound annual growth rate; YoY = year-over-year. [1]The company expects that, for the year ended December 31, 2024, reported total, neuroscience and oncology revenues will meet the guidance range provided on November 6, 2024. Jazz Pharmaceuticals plc has not finalized its financial results for the year ended December 31, 2024, and actual results may differ; [2]Based on mid-point of guidance provided by Jazz Pharmaceuticals plc on November 6, 2024; [3]Neuroscience revenues include high-sodium oxybate authorized generic royalties.

Pipeline

Focused Investments in Promising R&D Portfolio

Jazz Pharmaceuticals

Key Pipeline Programs



1L/2L = first- and second-line; BC = breast cancer; BTC = biliary tract cancer; DS = Dravet syndrome; ES = extensive-stage; GEA = gastroesophageal adenocarcinoma; HER2+ = human epidermal growth factor receptor 2 positive; LGS = Lennox-Gastaut syndrome; OS = overall survival; PFS = progression-free survival; SCLC = small cell lung cancer; sNDA = supplemental new drug application; T-DXd = trastuzumab deruxtecan; TSC = tuberous sclerosis complex.

Zanidatamab Has the Potential to Transform HER2-Targeted Therapies

Zanidatamab is a highly active, differentiated HER2-targeted bispecific mAb with compelling and durable survival data



Novel and Differentiated MOA

Best-in-Class Profile Addresses Unmet Need

Compelling Clinical Data in Multiple Indications

$2B+ Commercial Opportunity

HER2 = human epidermal growth factor receptor 2; mAb = monoclonal antibody; MOA = mechanism of action.

Rapidly Advancing Zanidatamab Development Program

2024

BTC
- ✓ Ziihera **approved in 2L BTC in 4Q24**
- ✓ **Initiated** 1L confirmatory trial
- ✓ **2L BTC MAA validated** by EMA

GEA
- ✓ **Enrollment on track** for Phase 3 HERIZON-GEA-01 trial

BC
- ✓ Phase 3 **EmpowHER-BC-303 trial initiated**

Pan Tumor
- ✓ Phase 2 **DiscovHER-Pan-206 trial initiated**

2025

BTC
- Potential **EU approval** as early as 2Q25

GEA
- HERIZON-GEA-01 **top-line results estimated 2Q25**
- Expect to **submit sBLA** in 1L
- Potential further development in neoadjuvant / adjuvant GEA population

2026 and Beyond

BTC
- Expect to **complete** 1L confirmatory trial

GEA
- Potential **1L approval and launch**
- Expanded market strategy

BC
- **Ongoing execution** of EmpowHER-BC-303 trial

Pan Tumor
- **Ongoing execution** of DiscovHER-Pan-206 trial

Goal: become the **HER2-targeted therapy of choice**

1L/2L= first- and second-line; BC = breast cancer; BTC = biliary tract cancer; EMA = European Medicines Agency; EU = European Union; GEA = gastroesophageal adenocarcinoma; HER2 = human epidermal growth factor receptor 2; MAA = marketing authorization application; sBLA = supplemental biologics license application.

Zepzelca: Positive Top-Line Results from 1L ES-SCLC Phase 3 Trial

IMforte Phase 3 Trial:

- Demonstrated **statistically significant** and **clinically meaningful improvement in OS** and **PFS** primary endpoints for 1L ES-SCLC
- Potential to **delay disease progression** and **extend survival for patients**
- Plan to **submit sNDA** for **1L ES-SCLC indication** in **1H25**

Significant unmet need:

- Expected median OS for 1L ES-SCLC patients is **~13 months**[2]
- In the U.S., there are **~30,000 1L SCLC patients,** with **~27,000** currently **treated** in 1L and ~17,000 treated in 2L[1]
- ~70% of 1L patients have extensive stage SCLC[1]



1L / 2L = first- and second-line; ES = extensive stage; LS = limited stage; OS = overall survival; PFS = progression-free survival; SCLC = small cell lung cancer; sNDA = supplemental New Drug Application. [1]Approximate U.S. SCLC patient numbers, sources: SEER Cancer Stat Facts https://seer.cancer.gov/statfacts/html/lungb.html, accessed April 19, 2019; American Cancer Society, https://www.cancer.org/cancer/small-cell-lung-cancer/about/what-is-small-cell-lung-cancer.html, accessed April 12, 2019; Kantar Health Treatment Architecture SCLC July 2018; Jazz primary market research May 2019; [2]Paz-Ares, L. et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022 Apr; 7(2):100408.

Key Commercial Products

Highly Differentiated Therapies Poised for Growth

Jazz Pharmaceuticals

Highly Differentiated Medicines for Patients with Serious Diseases

Top-line growth driven by **diversified businesses** spanning Sleep, Epilepsy and Oncology, **each annualizing >$1B**[1]

Oncology

ZIIHERA® (zanidatamab-hrii)

Potential to be the therapy of choice in multiple HER2+ tumors

ZEPZELCA™ (lurbinectedin)

#1 treatment in 2L ES-SCLC; expansion opportunity in 1L ES-SCLC

RYLAZE® asparaginase erwinia chrysanthemi (recombinant)-rywn for injection 10mg/0.5mL per vial

Standard of care in pediatric ALL/LBL patients with asparaginase HSR reaction

Neuroscience

Epidiolex®

#1 branded treatment for epilepsy

xywav™

#1 branded treatment for narcolepsy and only approved IH therapy

Diverse product mix + strong cash flow generation

1L / 2L = first- and second-line; ALL/LBL = acute lymphoblastic leukemia / lymphoblastic lymphoma; ES-SCLC = extensive-stage small cell lung cancer; HER2+ = human epidermal growth factor receptor 2 +; HSR = hypersensitivity; IH = idiopathic hypersomnia. [1]Based on 3Q24 revenues.

Ziihera: Unique MOA Drives Compelling Clinical Profile and Patient Outcomes

ZIIHERA®
(zanidatamab-hrii)



Unique dual-targeting HER2 bispecific antibody provides differentiated treatment

Compelling and durable responses help drive **improved patient outcomes** in HER2+ patients

Favorable tolerability profile contributes to improved patient quality of life

Combination data supports **ability to combine with other agents** in multiple HER2+ indications

HER2 = human epidermal growth factor receptor 2; MOA = mechanism of action.

BTC Launch: Building Momentum for Multiple Indications

ZIIHERA® (zanidatamab-hrii)

Ziihera Clinical Data

51.6%
Overall Response Rate[1]

14.9m
Median Duration of Response[1]

2.5%
Discontinuation Rate[1]

Mark
Ziihera patient living with Biliary Tract Cancer

Launch objectives

Establish Ziihera as the standard of care for 2L HER2+ BTC

Build momentum for Ziihera's potential as a transformative next-generation HER2-targeting agent

2L = second line; ASCO = American Society of Clinical Oncology; BTC = biliary tract cancer; HER2 = human epidermal growth factor receptor 2; M = month.[1]Data as presented by Pant et al. at ASCO 2024.

BTC Launch Driven by Proven Jazz Oncology Team and Infrastructure

Right Team, Right Capabilities

- Proven team with **deep oncology experience, including extensive expertise in the HER2 therapy space** will help drive **additional adoption and uptake**
- **Infrastructure in place** for a successful Ziihera launch

Key Customer Focus

- **Significant overlap** in existing call universe covering key customers and accounts
- Leverage Jazz's **established presence** across sales, marketing, medical and access

Robust Access and Patient Support Services

- Access, distribution, reimbursement, and patient support services **ensure customers can readily order Ziihera, help patients navigate reimbursement approvals, and provide patient support** through dedicated Jazz Resources and the JazzCares suite of services

BTC = biliary tract cancer; HER2 = human epidermal growth factor receptor 2.

Zanidatamab: De-Risked Near-Term Opportunity with $2B+ Peak Potential

Significant regulatory progress:

- Ziihera **now approved** in the U.S. for the treatment of adults with previously treated, unresectable or metastatic HER2+ (IHC3+) BTC
- EMA **validated MAA;** potential **approval as early as 2Q25**

Biliary Tract Cancer

Initiated U.S. launch activities in 2L BTC

1L BTC **confirmatory trial ongoing**

HERIZON-BTC-01: **Updated data at ASCO**

~12,000
BTC cases annually[2] in U.S., Europe[3] and Japan

Gastroesophageal Adenocarcinoma

Path to approval in 1L GEA with sBLA submission

HER2+/PD-L1 negative: opportunity to **address unmet need** and **replace trastuzumab**[1]

HER2+/PD-L1 positive: opportunity to replace trastuzumab as **HER2-targeted therapy of choice**[1]

Opportunity to **explore potential in neoadjuvant** populations[1]

~63,000
GEA cases annually[2] in U.S., Europe[3] and Japan

Breast Cancer

Expanded opportunity across lines of therapy[1]:
- Post T-DXd (Ph3 EmpowHER trial)
- Early lines of therapy (neoadjuvant)
- Novel combinations

Initiated Ph3 EmpowHER trial 2H24:
- Zanidatamab + chemo vs. tras + chemo in patients with HER2+ BC whose disease has progressed on previous T-DXd treatment

Potential for **novel chemo-free regimen** for **HER2+/HR+** patients[1]

Ongoing trials in early breast cancer:
- I-SPY2 Trial[4]
- MD Anderson collaboration

~150,000
BC cases annually[5] in U.S., Europe[3] and Japan

Other HER2-Expressing Cancers

Broad potential beyond BTC, GEA, and BC in multiple HER2-expressing indications **based on compelling clinical activity from early trials**[6]:
- Colorectal
- NSCLC
- Ovarian
- Endometrial
- Pancreatic
- Bladder
- Salivary Gland
- Ampullary
- Other HER2-expressing solid tumors

Initiated Phase 2 DiscovHER-Pan-206
- Zanidatamab monotherapy in previously-treated patients with no available treatment options

Broad Potential
Beyond BTC, GEA, and BC

1L/2L = first- and second line; ASCO = American Society of Clinical Oncology; BC = breast cancer; BTC = biliary tract cancer; EMA = European Medicines Agency; GEA = gastroesophageal adenocarcinoma; HER2 = human epidermal growth factor receptor 2; HR+ = hormone receptor positive; IHC = immunohistochemistry; MAA = marketing authorization application; NSCLC = non-small cell lung cancer; PD-L1 = programmed cell death ligand 1; sBLA = supplemental biologics license application; T-DXd = trastuzumab deruxtecan; tras = trastuzumab. [1]Pending regulatory approvals; [2]Incidence sources: Kantar reports, ToGA surveillance report; SEER, cancer.gov; ClearView Analysis; GLOBOCAN, Data on file; [3]Major markets, U.K, France, Germany, Spain, Italy; [4]NCT01042379, in collaboration with QuantumLeap Healthcare Collaborative; [5]Incidence source estimates derived from multiple sources: Decision Resources Group, Kantar Health, Jazz Market Research, data on file; [6]Funda Meric-Bernstam et al, Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study, The Lancet Oncology, Volume 23, Issue 12, 2022, Pages 1558-1570, ISSN 1470-2045, https://doi.org/10.1016/S1470-2045(22)00621-0.

Zepzelca: Opportunity to Redefine 1L SCLC Treatment Paradigm

Donna
Former Zepzelca patient living with SCLC

ZEPZELCA® (lurbinectedin) for injection 4 mg

Well-established as 2L SCLC treatment of choice

- **>$1.1 billion**[1] in revenue since launch in mid-2020

Plan to submit sNDA for 1L ES-SCLC in 1H25

- Reported **statistically significant** and **clinically meaningful OS and PFS results from the Phase 3 trial** in combination with Tecentriq® (atezolizumab), conducted in collaboration with Roche[2]
- **Significant unmet need**: expected **median OS** for ES 1L SCLC patients is **~13 months**[3]
- Potential to **increase duration of response** with earlier line patients
- In the U.S., there are **~30,000 1L SCLC patients**, with **~27,000** currently treated in 1L and **~17,000** treated in 2L[4]

1L/2L = first- and second-line; ES = extensive-stage; OS = overall survival; PFS = progression-free survival; SCLC = small cell lung cancer; sNDA = supplemental New Drug Application. [1]Net product sales from launch in July 2020 to September 30, 2024; [2]F. Hoffmann-La Roche Ltd.; [3]Paz-Ares, L. et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022 Apr; 7(2):1004008; [4]Approximate U.S. SCLC patient numbers, sources: SEER Cancer Stat Facts https://seer.cancer.gov/statfacts/html/lungb.html, accessed April 19, 2019, American Cancer Society, https://www.cancer.org/cancer/small-cell-lung-cancer/about/what-is-small-cell-lung-cancer.html, accessed April 12, 2019, Kantar Health Treatment Architecture SCLC July 2018, Jazz primary market research May 2019.

Rely on Rylaze: Critical Component of U.S. ALL/LBL Treatment Protocols

Willow
Rylaze patient diagnosed with ALL

RYLAZE® asparaginase erwinia chrysanthemi (recombinant)-rywn for injection 10mg/0.5mL per vial

ENRYLAZE

Sustained asparaginase activity over the course of therapy essential to treatment success of ALL/LBL patients[1]

- **~$1.1 billion**[2] in revenue since launch in mid-2021
- **Only therapy available** to patients in the U.S. who have a hypersensitivity reaction to *E. coli*-derived asparaginase

Continued strong demand driven by:

- Increased use in adolescent/young adult setting
- Switching to Rylaze at first sign of hypersensitivity reaction and due to treatment-related issues

ALL/LBL = acute lymphoblastic leukemia / lymphoblastic lymphoma. [1]Salzer W, Bostrom B, Messinger Y, et al. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(8):1797-1806; [2]Global net product sales from launch in July 2021 to September 30, 2024.

Epidiolex: Durable Growth; High Unmet Need in Pediatric Onset Epilepsy

Corey
Epidiolex patient living with LGS

Epidiolex® Epidyolex® cannabidiol Oral solution

Broad spectrum efficacy through novel mechanism of action

- Poised to reach **blockbuster status** in 2025
- Continued education on **synergies from treatment in combination with clobazam**
- **Further data generation**, including beyond-seizure benefits from the EpiCom[1] study in TSC and nurse-reported responses to the BECOME[2,3] survey in long-term care facilities presented at AES 2024
- Launched **Nurse Navigator program** to help patients and families address medication-related topics
- Additional opportunity to drive growth in **adult patient setting**

AES = American Epilepsy Society; LGS = Lennox-Gastaut syndrome; TSC = tuberous sclerosis complex. [1]Eeghen, AM, Thiele, EA, et al. Poster presented at: World Congress of Neurology, October 15-19, 2023; [2]Salazar TD, Berg A, Danese SR, et al. Poster presented at: American Epilepsy Society Annual Meeting; December 3-7, 2021; Chicago, IL; [3]Berg A, Perry MS, Salazar TD et al. Poster presented at: American Epilepsy Society Annual Meeting; December 3-7, 2021; Chicago, IL.

Xywav: Differentiated by Low Sodium; IH Provides Growth Opportunity

Cindy
Xywav patient living with IH

xywav™

- **Annualizing over $1.5 billion**[1] as of 3Q24
- Xywav remains **#1 branded treatment** for narcolepsy
- Xywav is the **only approved oxybate therapy** that **doesn't** carry a **warning** and **precaution** related to **high sodium intake**
- **FDA** published its summary of **clinical superiority findings** stating Xywav is clinically superior to Xyrem by **means of greater safety**
- **Positive impact** from **Field Nurse Educator program** supporting both narcolepsy and IH
- See **most opportunity for growth in IH** as the only approved therapy to treat IH and no near-term competition

FDA = Food and Drug Administration; IH = idiopathic hypersomnia. [1]Based net product sales reported for quarter ended September 30, 2024.

Well-Positioned to Deliver Long-Term Value

Operational Excellence and Commercial Execution

Jazz Pharmaceuticals

Delivering Significant Value Through Strategic Capital Allocation

STRONG FINANCIAL POSITION

~$1.0B
Cash from operations[1]

$2.6B
Cash, cash equivalents and investments[2]

$885M
Undrawn revolving credit facility[3]

DISCIPLINED CAPITAL DEPLOYMENT

COMMERCIAL GROWTH
New indications
Geographic expansion

PIPELINE EXPANSION
Advancing internal assets
Licensing new assets

OPERATIONAL EXCELLENCE
Disciplined and strategic capital allocation
Maximize value

STRATEGIC PRIORITIES

Diversified and growing revenue base

Differentiated pipeline to support future growth

Corporate development contributes to growth and diversification

[1]For the nine months ended September 30, 2024; [2]As of September 30, 2024; [3]As of December 31, 2024.

Well-Positioned to Deliver Meaningful Shareholder Value

COMMERCIAL EXECUTION

ZIIHERA® (zanidatamab-hrii) — **Executing launch** in 2L BTC

Epidiolex® / Epidyolex® cannabidiol Oral solution — Reaching **blockbuster status**

xywav™ — **Meaningful growth** opportunity in IH

ZEPZELCA™ (lurbinectedin) — **Treatment of choice** in 2L SCLC

RYLAZE® asparaginase erwinia chrysanthemi (recombinant)-rywn for injection 10mg/0.5mL per vial / ENRYLAZE — **Near universal adoption** in U.S. pediatric protocols

PIPELINE CATALYSTS

Zanidatamab

Phase 3 **1L GEA top-line data**: estimated 2Q25

Potential EU **2L BTC approval** as early as 2Q25

Phase 3 **EmpowHER late-line BC** trial is enrolling

Zepzelca

Expect to **submit sNDA** for 1L ES-SCLC in 1H25

CORPORATE DEVELOPMENT

Continued focus on **diversifying transactions** to **drive long-term growth and value**

1L/2L = first- and second-line; BC = breast cancer; BTC = biliary tract cancer; ES = extensive stage; EU = European Union; GEA = gastroesophageal adenocarcinoma; IH = idiopathic hypersomnia; SCLC = small-cell lung cancer; sNDA = supplemental new drug application.

Q&A

Jazz Pharmaceuticals

Thank You

Jazz Pharmaceuticals